查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1854501

醫療設備報銷市場按支付方、器材類型、器材分類、應用和最終用戶分類－2025-2032年全球預測

Medical Devices Reimbursement Market by Payer Outlook, Device Type, Device Classification, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫療設備報銷市場規模將達到 1,0586 億美元，複合年成長率為 7.93%。

關鍵市場統計數據
基準年2024年 5748億美元
預計年份：2025年 6182.5億美元
預測年份 2032 10586億美元
複合年成長率 (%) 7.93%

不斷變化的健保報銷環境、監管促進因素和相關人員的獎勵影響著醫療設備的採用和臨床路徑。

醫療設備報銷格局正經歷著重大變革，其驅動力包括支付方的優先事項、監管審查以及臨床護理領域技術的快速創新。價值鏈上的相關人員正在重新評估醫療設備如何反映價值、如何做出報銷決策，以及商業策略如何適應對臨床結果和醫療總成本日益嚴格的審查。因此，製造商、醫療服務提供者和支付方正朝著以證據主導的路徑邁進，這些路徑強調長期績效、互通性和以患者為中心的結果。

在實踐中，這意味著醫療器材開發商必須超越技術規格，建構以可靠的衛生經濟學證據和真實世界結果為支持的論述。同時，支付方正在擴展其評估新技術的標準，將療效比較、預算影響和長期使用模式納入考量。因此，報銷策略不再是產品開發過程中的次要考慮因素，而是不可或缺的一部分。政策、採購和臨床應用之間的相互作用將決定哪些創新能夠轉化為永續的臨床實踐。

以價值為導向的醫療服務、數位整合、供應鏈韌性以及監管預期如何重塑報銷模式和商業策略

市場力量和政策轉變正在引發醫療設備評估、採購和報銷方式的變革，對製造商和支付者都提出了新的要求。以價值為導向的醫療改革和價格透明化舉措優先考慮可衡量的患者療效和對總成本的影響，促使支付方和整合醫療服務網路傾向於選擇能夠在整個治療過程中展現可衡量獲益的器械。同時，數位醫療的整合和軟體賦能的器材正在模糊傳統產品的界限，因此需要建立新的報銷機制，將軟體更新、雲端服務和數據主導的臨床決策支援納入考量。

此外，供應鏈韌性正從後勤部門層面轉向策略性報銷促進因素。採購方如今在簽訂合約時，往往會將供應的連續性和國內採購納入考量。監管機構對網路安全、互通性和上市後監測的重視，提高了市場准入的證據門檻。因此，臨床證據的產生、真實世界績效監測以及與支付方的互動策略正日益成為關鍵的成功因素。總而言之，這些動態正在重塑商業模式，並促使製造商、醫療服務提供者和支付者之間開展合作，共同設計能夠協調各相關人員獎勵的支付結構。

評估不斷變化的關稅壓力將如何影響醫療設備產業的供應鏈、採購選擇、定價對話和證據策略。

提高進口壁壘或改變關稅結構的政策會對採購、製造、定價和支付方談判產生連鎖反應，但在全球化供應鏈普遍存在的醫療設備產業，這些影響尤其敏感。當零件、原料或成品徵收關稅時，製造商將面臨不斷上漲的投入成本，必須做出策略決策，例如自行承擔、轉嫁給買家或重新調整供應鏈。為此，一些公司正在加速近岸外包、實現供應商多元化或進行垂直整合，以確保利潤率和交貨時間。這些營運調整往往會影響與醫院和醫療系統的合約談判，因為這些機構可能會尋求價格保護或與交付績效掛鉤的附加採購條件。

從報銷角度來看，關稅會使定價對話變得複雜，因為支付方通常根據臨床和經濟價值而非短暫的貿易政策波動來評估醫療設備。儘管如此，醫療設備採購成本的持續上漲可能會促使支付方優先考慮那些有望降低醫療總成本並改善長期療效的替代療法，從而更加關注單件醫療設備的採購成本和醫療設備利用率。此外，關稅可能會獎勵製造商透過減少再入院率、縮短住院時間和降低後續護理成本來證明其產品能夠抵消成本。因此，隨著關稅帶來的成本壓力日益顯現，證據生成策略和合約彈性對於維持醫療產品的可及性和普及率至關重要。

最後，關稅將影響策略投資決策。資本配置將轉向調整生產佈局和提升分析能力，以量化價格變化如何影響健保報銷談判。透過主動模擬關稅情境並將其納入與支付方的討論，製造商可以提供切實可行的緩解策略，並在貿易動態變化的過程中維持醫療覆蓋範圍。

將支付方類型、醫療設備類別、分類、臨床用途和最終用戶偏好與報銷動態和採用路徑聯繫起來的精細細分洞察

細緻的細分框架清楚地揭示了報銷壓力點和市場推廣機會的交會點。它首先分析了私人和公共支付方在支付理念上的差異：私人支付方通常強調管理式醫療路徑和基於價值的契約，而公共支付方則更注重標準化的福利結構和監管合規。按產品類型（耗材/拋棄式、診斷影像設備、行動輔助設備和治療設備）進行細分，突顯了不同的商業性和實質需求。在耗材方面，注射器、針頭和創傷護理產品通常以單價和供應可用性為競爭優勢；而診斷成像設備，例如CT掃描儀、MRI系統、超音波診斷設備和X光系統，則需要大量的資本投資、互通性認證和長期服務合約。治療設備包括透析設備、輸液系統和呼吸治療設備，其中呼吸治療設備還包括氧氣療法設備和人工呼吸器，每種設備都有其獨特的用途和臨床證據要求。

器械分類也至關重要：I類器械通常比II類器械面臨更輕的監管和研發負擔，II類器械通常需要基於性能數據和預測數據獲得批准。 III類創新器材通常需要嚴格的臨床試驗和廣泛的上市後追蹤。應用細分進一步區分了心臟病學、神經病學、腫瘤學和骨科等領域的支付方和臨床優先事項。心臟病學分支，例如心臟節律管理和介入性心臟病循環系統，強調器械的長期性和減少併發症；而神經科分支，例如腦脊髓液管理和神經刺激，則要求持久的療效和安全性監測。同時，在整形外科分支中，關節重組和脊椎手術器械強調恢復活動能力和長期植入物存活率。最後，終端使用者細分區分了門診手術中心、家庭醫療保健和醫院/診所等部署管道，其中醫院/診所進一步細分為植入和門診病人護理環境，這兩種環境的採購方式、合約週期和使用動態存在顯著差異。

要確保在這些相互交織的維度上實現持久覆蓋和普及，就需要製定能夠反映每個細分市場相關的技術概況、臨床應用和購買行為的報銷策略。

美洲、歐洲、中東和非洲以及亞太地區不同的支付方體系、採購實務和監管方式將如何塑造不同的打入市場策略

美洲、歐洲、中東和非洲以及亞太地區的區域促進因素以獨特的方式影響報銷法規、採購行為和路徑選擇，為醫療器材製造商創造了不同的策略重點。在美洲，尤其是美國，報銷決策深受私人支付方和公共計畫等複雜因素的影響，價值論證、捆綁銷售獎勵和醫院的購買力指南商業化策略。在拉丁美洲市場，不斷變化的法規環境和對成本控制日益重視，往往需要採用適應性定價模式和區域合作。

在歐洲、中東和非洲，各國醫療保健體系各不相同。有些國家採用集中採購模式，這不僅創造了擴充性的競標機會，也帶來了報銷標準差異所帶來的挑戰。各國衛生技術評估機構通常透過評估療效比較和預算影響來確定醫保覆蓋範圍，而區域監管協調工作則越來越重視上市後證據和器械可追溯性。在亞太地區，數位醫療的快速普及和政府主導的醫療基礎設施投資正在推動對先進診斷影像、治療設備和居家照護解決方案的需求。然而，打入市場策略必須根據當地的報銷框架進行調整，這些框架涵蓋了從完全公共資助的公共體係到公私混合模式的各種情況，製造商還必須應對各種註冊要求和價格管制。

綜上所述，這些區域差異需要製定差異化的商業化藍圖，使臨床證據的產生、定價策略和供應鏈佈局與區域報銷優先事項和採購機制保持一致。

為什麼領先的醫療器材製造商正在整合臨床證據、數位化服務和供應鏈投資，以改善報銷、價格一致性和長期市場接受度？

領先的醫療設備製造商正在整合臨床證據產生、數位化服務和供應鏈韌性，以保持競爭力並確保獲得良好的報銷結果。現有醫療技術公司正在投資於整合硬體、軟體和服務的一體化醫療解決方案，以期在改善患者預後和提高診療流程效率方面取得可衡量的進步，同時尋求與數位醫療創新者合作，以加速遠距監測和遠端醫療醫療模式的發展。這些策略正幫助企業將與支付方的溝通重點從單價轉向長期價值，從而催生出諸如績效合約和人群風險分擔安排等新型合約機制。

同時，專注於大批量耗材的公司正優先考慮生產規模、成本控制和分銷可靠性，以滿足高頻次的臨床需求。資本密集型診斷影像和治療平台製造商則優先考慮服務協議、生命週期管理和互通性，以保護裝置量並為高價定價提供基礎。各公司正在擴展其真實世界證據項目，利用索賠層面的分析、註冊登記和上市後監測來證明安全性、比較療效和經濟影響。隨著成熟企業和新興企業尋求擴展臨床數據能力、擴大地域覆蓋範圍並整合數位健康產品以滿足支付方期望和醫療服務提供方工作流程，策略併購和合作也變得越來越普遍。

製造商可採取切實可行的策略性舉措，使證據、合約和營運彈性與支付方和提供者對持久可及性的期望保持一致。

行業領導者應採取整合方法，將證據生成、商業性合約和營運韌性相結合，以避免報銷流程的複雜性並加速產品推廣。首先，在產品開發早期階段就應納入衛生經濟學和結果研究，以產生前瞻性研究設計和真實世界證據，從而消除支付方對長期價值和預算影響的擔憂。其次，應與支付方和醫療系統合作，採用基於結果的協議和打包支付模式等合作合約模式，以分擔風險並展現與整體醫療成本目標的一致性。第三，應透過供應商多元化、區域化生產選擇以及合約保障措施來增強供應鏈韌性，從而確保供應的連續性並促進與買家進行價格穩定談判。

此外，我們將投資於數位化準備和互通性，以支援遠端監測、上市後監測和資料收集，從而證實臨床效益的聲明。我們將透過建構上市後監測系統和事件回應能力，加強監管和網路安全準備，使支付方和醫療服務提供者對器材安全性和資料完整性放心。最後，我們將制定適應當地報銷環境的市場策略，使定價、循證依據和服務模式與公共和私人支付方的獨特期望以及門診、居家醫療和醫院環境的採購動態相匹配。透過協同利用這些要素，製造商可以提高獲得有利保險覆蓋、協商永續價格和推動持久臨床應用的能力。

一個透明的研究框架，包括相關人員訪談、監管和臨床證據綜合分析以及三角驗證分析，以檢驗報銷方面的見解。

本分析所依據的研究整合了政策審查、監管指南、臨床文獻和相關人員訪談，從而對報銷動態提供了多角度的視角。主要資料來源包括對支付方決策者、醫院採購負責人、臨床醫生和醫療器材商業化高階主管的結構化訪談，以了解觀點對證據要求、合約偏好和推廣障礙的看法。次要資料來源包括對臨床研究、衛生技術評估報告和監管文件的系統綜述，以確定證據閾值和上市後義務。

分析方法將定性見解與索賠層面的定量訊號進行三角驗證，以識別核保決策、使用趨勢和支付方談判策略中的重複模式。證據綜合包括檢驗透過新型臨床項目和支付模式實現差異化准入的醫療設備案例研究，以及探討政策和貿易發展如何改變採購獎勵的情境分析。我們始終強調資料來源、訪談通訊協定和納入標準的可重複記錄，以確保透明度。我們進行了敏感性檢查，並由臨床和報銷專家進行同行評審，以驗證解釋的準確性，並確保結論反映真實的決策情境和可實施的策略。

本文綜合闡述了整合證據產生、適應性合約和在地化客製化為何決定著醫保報銷的成功和臨床應用。

支付方日益嚴格的審查、數位化創新以及供應鏈的迫切需求，共同為力求獲得報銷核准和廣泛臨床應用的醫療器材製造商帶來了挑戰和機會。成功越來越取決於能否證明產品具有顯著的臨床療效、量化總成本影響，並提供能夠同時滿足公共和私人支付方需求的持久上市後監測承諾。那些將衛生經濟規劃融入產品開發、投資真實世界數據項目並採用靈活合約結構的公司，將更有能力應對複雜的醫保報銷流程並保持商業性成長。

同時，區域差異和細分市場的具體情況需要製定獨特的策略，以尊重當地的採購慣例和臨床工作流程。透過將產品設計、證據產生和商業模式與這些背景因素結合，製造商可以加速產品在目標細分市場和醫療環境中的應用。最終，將報銷視為核心策略職能，並由臨床、監管、商業和營運團隊協同合作的公司，將確保更早獲得市場准入、建立更牢固的支付方關係，以及實現更可預測的使用軌跡。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合真實世界證據以確保數位健康設備快速報銷
  • 基於價值的定價模式的變化正在影響保險公司對新型診斷影像系統的承保範圍。
  • 隨著聯邦醫療保險和醫療補助計劃的擴展，遠端患者監護報銷代碼應運而生
  • 為精準手術機器人爭取高額報銷率的談判策略
  • 醫療技術評估方法對人工智慧診斷設備應用的影響
  • 擴大打包支付模式會影響整形外科植入手術的報銷。
  • 監管改革簡化了遠端醫療醫療設備服務的編碼和計費流程

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章醫療設備報銷市場（按支付方分類）展望

  • 私人的
  • 公共

第9章 按器材類型分類的醫療設備報銷市場

  • 耗材和拋棄式用品
    • 注射器和針頭
    • 創傷護理產品
  • 診斷影像設備
    • 電腦斷層掃描（CT）掃描儀
    • 磁振造影（MRI）設備
    • 超音波設備
    • X光系統
  • 行動輔助設備
  • 治療設備
    • 透析設備
    • 輸液系統
    • 呼吸治療裝置
      • 氧氣療法設備
      • 人工呼吸器

第10章 按器材分類分類的醫療設備報銷市場

  • 一級
  • II 類
  • 三級

第11章 按應用分類的醫療設備報銷市場

  • 心臟病學
    • 心臟節律管理
    • 介入性心臟病學器械
  • 神經病學
    • 腦脊髓液管理
    • 神經刺激設備
  • 腫瘤學
    • 化療的實施
    • 放射治療設備
  • 整形外科
    • 關節重組
    • 脊椎外科手術器械

第12章醫療設備報銷市場（依最終用戶分類）

  • 門診手術中心
  • 家庭醫療保健
  • 醫院和診所
    • 住院治療
    • 門診治療

第13章 各地區醫療設備報銷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章醫療設備報銷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國醫療設備報銷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AiM GmbH
    • Allianz SE
    • Anco Insurance
    • Anthem Insurance Companies, Inc.
    • Aviva PLC
    • BNP Paribas
    • CVS Health Corporation
    • European Med Tech and IVD Reimbursement Consulting Ltd.
    • Hamilton Leigh Ltd.
    • HUB International Limited
    • Humana Inc.
    • MCRA, LLC
    • mdiConsultants, Inc.
    • Medmarc Insurance Group
    • North American Science Associates, Inc.
    • Reliance Nippon Life Insurance Company
    • UnitedHealth Group
    • UnitedHealth Group Incorporated
    • WellCare Health Plans, Inc.
    • WS Value & Dossier GmbH
    • XIFIN, Inc.
Product Code: MRR-205091A88A65

The Medical Devices Reimbursement Market is projected to grow by USD 1,058.60 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 574.80 billion
Estimated Year [2025] USD 618.25 billion
Forecast Year [2032] USD 1,058.60 billion
CAGR (%) 7.93%

A concise orientation to the evolving reimbursement environment, regulatory drivers, and stakeholder incentives reshaping device adoption and clinical pathways

The reimbursement landscape for medical devices is undergoing a decisive transition driven by payer priorities, regulatory scrutiny, and rapid innovation in clinical care. Stakeholders across the value chain are re-evaluating how devices demonstrate value, how coverage determinations are made, and how commercial strategies must adapt to tighter scrutiny of clinical outcomes and total cost of care. Consequently, manufacturers, providers, and payers are converging around evidence-driven pathways that emphasize longitudinal performance, interoperability, and patient-centered outcomes.

In practice, this means that device developers must move beyond technical specifications to craft narratives supported by robust health economic evidence and real-world outcomes. Simultaneously, payers are expanding the criteria they use to assess new technologies, incorporating comparative effectiveness, budget impact, and long-term utilization patterns. As a result, reimbursement strategy has become an essential component of product development rather than an afterthought. The interplay between policy, procurement, and clinical adoption will determine which innovations translate into sustainable clinical practice.

How value-based care, digital integration, supply resilience, and regulatory expectations are jointly reshaping reimbursement models and commercial strategies

Market forces and policy shifts are triggering transformative changes in how medical devices are assessed, procured, and reimbursed, creating new imperatives for manufacturers and payers alike. Value-based care reforms and price transparency initiatives are prioritizing measurable patient outcomes and total cost impact, prompting payers and integrated delivery networks to favor devices that can demonstrate measurable benefits across episodes of care. In parallel, digital health integration and software-enabled devices are blurring traditional product boundaries, necessitating fresh reimbursement constructs that account for software updates, cloud services, and data-driven clinical decision support.

Moreover, supply chain resilience has shifted from a back-office concern to a strategic reimbursement factor; purchasers now often factor in supply continuity and domestic sourcing into contracting decisions. Regulatory emphasis on cybersecurity, interoperability, and post-market surveillance has increased the evidentiary bar for market access. Consequently, clinical evidence generation, real-world performance monitoring, and payer engagement strategies are converging as critical success factors. Taken together, these dynamics are reshaping commercial models and incentivizing collaborations between manufacturers, providers, and payers to co-design payment structures that align incentives across stakeholders.

Assessing how evolving tariff pressures can ripple through supply chains, procurement choices, pricing dialogues, and evidence strategies across the medical device sector

Policies that raise import barriers or change tariff structures create ripple effects through procurement, manufacturing, pricing, and payer negotiations, with particular sensitivity in the medical device sector where globalized supply chains are common. When tariffs are applied to components, raw materials, or finished devices, manufacturers face higher input costs and must make strategic decisions about absorbing costs, passing them to buyers, or rebalancing supply chains. In response, some companies accelerate nearshoring, diversify supplier portfolios, or increase vertical integration to insulate margins and delivery timelines. These operational adjustments frequently influence contract negotiations with hospitals and health systems, which may seek price protections or conditional purchasing tied to delivery performance.

From a reimbursement perspective, tariffs complicate pricing dialogues because payers typically evaluate devices based on clinical and economic value rather than transient trade policy fluctuations. Nevertheless, sustained increases in acquisition costs tend to trigger greater attention to per-procedure costs and device utilization rates, encouraging payers to favor alternatives that promise lower total cost of care or improved long-term outcomes. In addition, tariffs can amplify incentives for manufacturers to demonstrate cost offsets via reduced readmissions, shorter length of stay, or decreased downstream therapy costs. As a result, evidence-generation strategies and contractual flexibility become essential to preserve access and uptake when tariff-driven cost pressures emerge.

Finally, tariffs influence strategic investment decisions. Capital allocation shifts toward manufacturing footprint adjustments and analytics capabilities that quantify how price changes affect reimbursement conversations. By proactively modeling tariff scenarios and integrating them into payer discussions, manufacturers can present credible mitigation plans and preserve coverage pathways despite evolving trade dynamics.

Granular segmentation insights linking payer type, device category, classification, clinical application, and end-user setting to reimbursement dynamics and adoption pathways

A nuanced segmentation framework clarifies where reimbursement pressure points and adoption opportunities intersect, beginning with payer outlook distinctions across Private and Public coverage environments where private insurers often emphasize managed care pathways and value-based contracting while public payers focus on standardized benefit structures and regulatory compliance. Device type segmentation highlights distinct commercial and evidentiary needs across Consumables and Disposables, Diagnostic Imaging Equipment, Mobility Aids, and Therapeutic Devices; within consumables, syringes and needles and wound care products typically compete on unit cost and supply reliability, whereas diagnostic imaging equipment such as CT scanners, MRI systems, ultrasound devices, and X-ray systems require substantial capital investment, interoperability credentials, and long-term service agreements. Therapeutic devices encompass dialysis equipment, infusion systems, and respiratory therapy devices, and the respiratory therapy subset includes oxygen therapy equipment and ventilators, each of which has unique utilization patterns and clinical evidence requirements.

Device classification also matters: Class I items generally face lighter regulatory and evidentiary burdens compared with Class II devices that often require performance data and predicate-based clearance, and Class III innovations typically demand rigorous clinical trials and extensive post-market follow-up. The application segmentation further differentiates payer and clinical priorities across cardiology, neurology, oncology, and orthopedics. Cardiology subdivisions like cardiac rhythm management and interventional cardiology devices focus on longevity and complication reduction, while neurology areas such as cerebrospinal fluid management and neurostimulation demand durable outcomes and safety monitoring. Oncology segments split between chemotherapy administration and radiation therapy equipment, each tied to complex treatment pathways, whereas orthopedics covering joint reconstruction and spinal surgery devices center on mobility restoration and longer-term implant survivorship. Finally, end-user segmentation delineates channels of adoption between ambulatory surgical centers, home healthcare, and hospitals and clinics, with the latter further segmented into in-patient care and out-patient care settings that differ markedly in purchasing practices, contracting cycles, and utilization dynamics.

Across these intersecting dimensions, tailored reimbursement strategies must reflect the technical profile, clinical footprint, and purchasing behavior associated with each segment to secure durable coverage and uptake.

How contrasting payer systems, procurement customs, and regulatory approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific dictate tailored market access strategies

Regional dynamics shape reimbursement rules, procurement behaviors, and pathway adoption in distinctive ways across the Americas, Europe Middle East & Africa, and Asia-Pacific, creating differing strategic priorities for device manufacturers. In the Americas, particularly within the United States, reimbursement decisions are heavily influenced by a complex mix of private insurers and public programs where value demonstration, bundling incentives, and hospital purchasing power guide commercialization tactics. Latin American markets in the region present variable regulatory environments and greater emphasis on cost-containment tactics, often requiring adaptable pricing models and regional partnerships.

In Europe, the Middle East & Africa, heterogeneous national health systems and centralized procurement in some countries create both opportunities for scalable tenders and challenges related to divergent reimbursement criteria. National health technology assessment bodies frequently shape coverage decisions by assessing comparative effectiveness and budget impact, and regional regulatory alignment efforts place additional emphasis on post-market evidence and device traceability. In the Asia-Pacific region, rapid adoption of digital health and government-led investment in health infrastructure drive demand for advanced imaging, therapeutic devices, and home-based care solutions. However, market access strategies must be tailored to local reimbursement frameworks, which range from fully funded public systems to mixed public-private models, and manufacturers must navigate variable registration requirements and pricing controls.

Taken together, these regional contrasts require differentiated commercialization blueprints that align clinical evidence generation, pricing strategies, and supply chain footprints with local reimbursement priorities and procurement mechanisms.

Why top device manufacturers are combining clinical evidence, digital services, and supply chain investments to secure coverage, pricing parity, and long-term adoption

Leading device manufacturers are consolidating capabilities across clinical evidence generation, digital services, and supply chain resilience to maintain competitive positioning and secure favorable reimbursement outcomes. Established medtech firms are investing in integrated care solutions that combine hardware, software, and services to create measurable improvements in patient outcomes and pathway efficiency, while also seeking partnerships with digital health innovators to accelerate remote monitoring and telehealth-enabled care models. These strategies help firms shift conversations with payers from unit price to value delivered over time, enabling novel contracting mechanisms such as performance-based agreements and population-level risk-sharing arrangements.

Concurrently, companies that specialize in high-volume consumables emphasize manufacturing scale, cost discipline, and distribution reliability to meet the demands of high-frequency clinical settings. Manufacturers of capital-intensive diagnostic imaging and therapeutic platforms are prioritizing service agreements, lifecycle management, and interoperability to protect installed bases and justify premium pricing. Across the board, firms are expanding real-world evidence programs, leveraging claims-level analyses, registries, and post-market studies to demonstrate safety, comparative effectiveness, and economic impact. Strategic M&A and collaboration are common as incumbents and emerging firms seek to augment clinical data capabilities, extend geographic reach, and integrate digital health offerings that align with payer expectations and provider workflows.

Practical strategic moves for manufacturers to align evidence, contracting, and operational resilience with payer and provider expectations for durable access

Industry leaders should adopt an integrated approach that aligns evidence generation, commercial contracting, and operational resilience to navigate reimbursement complexity and accelerate adoption. First, embed health economics and outcomes research early in product development to produce prospective study designs and real-world evidence capable of addressing payer concerns about long-term value and budget impact. Second, pursue collaborative contracting models with payers and health systems, including outcome-based arrangements and bundled payment approaches, to share risk and demonstrate alignment with total cost of care objectives. Third, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and contractual safeguards that preserve continuity of supply and enable price stability discussions with buyers.

Furthermore, invest in digital enablement and interoperability to support remote monitoring, post-market surveillance, and data capture that substantiate claims about clinical benefit. Enhance regulatory and cybersecurity preparedness by building post-market surveillance systems and incident response capabilities that reassure payers and providers about device safety and data integrity. Lastly, tailor go-to-market strategies to local reimbursement environments by aligning pricing, evidence dossiers, and service models with the unique expectations of public and private payers as well as the purchasing dynamics of ambulatory, home care, and hospital settings. By operationalizing these elements in concert, manufacturers improve their ability to secure favorable coverage, negotiate sustainable pricing, and drive durable clinical adoption.

A transparent research framework combining stakeholder interviews, regulatory and clinical evidence synthesis, and triangulated analysis to validate reimbursement insights

The research underpinning this analysis synthesizes policy reviews, regulatory guidance, clinical literature, and stakeholder interviews to produce a multidimensional view of reimbursement dynamics. Primary inputs include structured interviews with payer decision-makers, hospital procurement leaders, clinicians, and device commercialization executives to capture perspectives on evidence requirements, contracting preferences, and adoption barriers. Secondary inputs involve systematic reviews of clinical studies, health technology assessment reports, and regulatory documents that illuminate evidentiary thresholds and post-market obligations.

Analytic methods rely on triangulation across qualitative insights and quantitative claims-level signals to identify recurring patterns in coverage decisions, utilization trends, and payer negotiation tactics. Evidence synthesis includes examination of case studies where devices achieved differentiated access through novel clinical programs or payment models, as well as scenario analysis to explore how policy or trade developments may alter procurement incentives. Throughout, emphasis is placed on reproducible documentation of data sources, interview protocols, and inclusion criteria to ensure transparency. Sensitivity checks and peer review by clinical and reimbursement experts were applied to validate interpretations and ensure that conclusions reflect realistic decision-making contexts and implementable strategies.

Synthesis of why integrated evidence generation, adaptive contracting, and regional customization determine reimbursement success and clinical adoption

The convergence of elevated payer scrutiny, digital innovation, and supply chain imperatives creates both challenge and opportunity for device manufacturers seeking reimbursement approval and widespread clinical adoption. Success increasingly hinges on the ability to demonstrate meaningful clinical outcomes, quantify total cost implications, and present durable post-market surveillance commitments that satisfy both private and public payers. Firms that integrate health economic planning into product development, invest in real-world data programs, and pursue flexible contracting arrangements will be best placed to navigate reimbursement complexity and sustain commercial growth.

In parallel, regional differentiation and segment-specific nuances require tailored strategies that respect local procurement practices and clinical workflows. By aligning product design, evidence generation, and commercial models with these contextual factors, manufacturers can accelerate uptake in targeted segments and settings. Ultimately, the companies that treat reimbursement as a core strategic function-coordinated across clinical, regulatory, commercial, and operations teams-will secure earlier access, stronger payer relationships, and more predictable utilization trajectories.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real world evidence to secure accelerated reimbursement for digital health devices
  • 5.2. Shifts in value based pricing models impacting insurer coverage of novel diagnostic imaging systems
  • 5.3. Emergence of remote patient monitoring reimbursement codes under Medicare and Medicaid expansions
  • 5.4. Negotiation strategies for achieving premium reimbursement rates for precision surgical robots
  • 5.5. Impact of health technology assessment methodologies on adoption of AI enabled diagnostic devices
  • 5.6. Expansion of bundled payment models affecting reimbursement for orthopaedic implant procedures
  • 5.7. Regulatory changes streamlining coding and billing for telehealth enabled medical device services

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Devices Reimbursement Market, by Payer Outlook

  • 8.1. Private
  • 8.2. Public

9. Medical Devices Reimbursement Market, by Device Type

  • 9.1. Consumables and Disposables
    • 9.1.1. Syringes & Needles
    • 9.1.2. Wound Care Products
  • 9.2. Diagnostic Imaging Equipment
    • 9.2.1. Computed Tomography (CT) Scanners
    • 9.2.2. Magnetic Resonance Imaging (MRI) Equipment
    • 9.2.3. Ultrasound Devices
    • 9.2.4. X-Ray Systems
  • 9.3. Mobility Aids
  • 9.4. Therapeutic Devices
    • 9.4.1. Dialysis Equipment
    • 9.4.2. Infusion Systems
    • 9.4.3. Respiratory Therapy Devices
      • 9.4.3.1. Oxygen Therapy Equipment
      • 9.4.3.2. Ventilators

10. Medical Devices Reimbursement Market, by Device Classification

  • 10.1. Class I
  • 10.2. Class II
  • 10.3. Class III

11. Medical Devices Reimbursement Market, by Application

  • 11.1. Cardiology
    • 11.1.1. Cardiac Rhythm Management
    • 11.1.2. Interventional Cardiology Devices
  • 11.2. Neurology
    • 11.2.1. Cerebrospinal Fluid Management
    • 11.2.2. Neurostimulation Devices
  • 11.3. Oncology
    • 11.3.1. Chemotherapy Administration
    • 11.3.2. Radiation Therapy Equipment
  • 11.4. Orthopedics
    • 11.4.1. Joint Reconstruction
    • 11.4.2. Spinal Surgery Devices

12. Medical Devices Reimbursement Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals & Clinics
    • 12.3.1. In-patient Care
    • 12.3.2. Out-patient Care

13. Medical Devices Reimbursement Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Medical Devices Reimbursement Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Medical Devices Reimbursement Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AiM GmbH
    • 16.3.2. Allianz SE
    • 16.3.3. Anco Insurance
    • 16.3.4. Anthem Insurance Companies, Inc.
    • 16.3.5. Aviva PLC
    • 16.3.6. BNP Paribas
    • 16.3.7. CVS Health Corporation
    • 16.3.8. European Med Tech and IVD Reimbursement Consulting Ltd.
    • 16.3.9. Hamilton Leigh Ltd.
    • 16.3.10. HUB International Limited
    • 16.3.11. Humana Inc.
    • 16.3.12. MCRA, LLC
    • 16.3.13. mdiConsultants, Inc.
    • 16.3.14. Medmarc Insurance Group
    • 16.3.15. North American Science Associates, Inc.
    • 16.3.16. Reliance Nippon Life Insurance Company
    • 16.3.17. UnitedHealth Group
    • 16.3.18. UnitedHealth Group Incorporated
    • 16.3.19. WellCare Health Plans, Inc.
    • 16.3.20. WS Value & Dossier GmbH
    • 16.3.21. XIFIN, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MEDICAL DEVICES REIMBURSEMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MEDICAL DEVICES REIMBURSEMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MEDICAL DEVICES REIMBURSEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SYRINGES & NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY WOUND CARE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI) EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY X-RAY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY MOBILITY AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIALYSIS EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INFUSION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OXYGEN THERAPY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CEREBROSPINAL FLUID MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROSTIMULATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CHEMOTHERAPY ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RADIATION THERAPY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY JOINT RECONSTRUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SPINAL SURGERY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY IN-PATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY OUT-PATIENT CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY PAYER OUTLOOK, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CONSUMABLES AND DISPOSABLES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DIAGNOSTIC IMAGING EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY RESPIRATORY THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY DEVICE CLASSIFICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS MEDICAL DEVICES REIMBURSEMENT MARKET SIZE, BY ORTHOPEDICS, 2025-2032 (USD